The bone marrow niche has mystified scientists for many years, leading to widespread
investigation to shed light into its molecular and cellular composition. Considerable efforts …

Hematopoietic stem-cell transplantation, which is used to treat both malignant and
nonmalignant conditions, was first conceived more than 50 years ago, but problems …

Transplantation of hematopoietic stem cells (HSCs) from human umbilical cord blood
(hUCB) holds great promise for treating a broad spectrum of hematological disorders …

Now available in a thoroughly revised Twelfth Edition, Wintrobe's Clinical Hematology
continues to be an industry leader with its ability to correlate basic science with the clinical …

Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result from
inadequate numbers of progenitor cells in the graft and is associated with increased early …

Background Umbilical-cord blood (UCB) is increasingly considered as an alternative to
peripheral blood progenitor cells (PBPCs) or bone marrow, especially when an HLA …

Background Data regarding the outcome of cord-blood transplantation in adults are scant,
despite the fact that these grafts are increasingly used in adults. Methods We compared the …

Background Although umbilical cord blood is an accepted alternative to bone marrow for
transplantation, allele-matched bone marrow is generally regarded as the preferred graft …

Umbilical cord blood transplantation (UCBT) has been performed in the clinic for over 30
years. The biological and immunological characteristics of umbilical cord blood (UCB) have …

Hematopoietic stem cell homing and engraftment are crucial to transplantation efficiency,
and clinical engraftment is severely compromised when donor-cell numbers are limiting. The …